Literature DB >> 29382707

Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody-Drug Conjugates.

Hui Zhao1, John Atkinson1, Sara Gulesserian1, Zhilan Zeng1, Jenny Nater1, Jimmy Ou1, Peng Yang1, Karen Morrison1, Jeffrey Coleman1, Faisal Malik1, Pia Challita-Eid1, Sher Karki1, Hector Aviña1, René Hubert1, Linnette Capo1, Josh Snyder1, Sung-Ju Moon1, Roland Luethy1, Brian A Mendelsohn1, David R Stover1, Fernando Doñate2.   

Abstract

AGS-16C3F is an antibody-drug conjugate (ADC) against ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) containing the mcMMAF linker-payload currently in development for treatment of metastatic renal cell carcinoma. AGS-16C3F and other ADCs have been reported to cause ocular toxicity in patients by unknown mechanisms. To investigate this toxicity, we developed an in vitro assay using human corneal epithelial cells (HCEC) and show that HCECs internalized AGS-16C3F and other ADCs by macropinocytosis, causing inhibition of cell proliferation. We observed the same mechanism for target-independent internalization of AGS-16C3F in fibroblasts and human umbilical vein endothelial cells (HUVEC). Macropinocytosis-mediated intake of macromolecules is facilitated by the presence of positive charges or hydrophobic residues on the surface of the macromolecule. Modification of AGS-16C3F, either by attachment of poly-glutamate peptides, mutation of residue K16 to D on AGS-16C3F [AGS-16C3F(K16D)], or decreasing the overall hydrophobicity via attachment of polyethylene glycol moieties, significantly reduced cytotoxicity against HCECs and other primary cells. Rabbits treated with AGS-16C3F showed significant ocular toxicity, whereas those treated with AGS-16C3F(K16D) presented with less severe and delayed toxicities. Both molecules displayed similar antitumor activity in a mouse xenograft model. These findings establish a mechanism of action for target-independent toxicities of AGS-16C3F and ADCs in general, and provide methods to ameliorate these toxicities.Significance: These findings reveal a mechanism for nonreceptor-mediated toxicities of antibody drug conjugates and potential solutions to alleviate these toxicities. Cancer Res; 78(8); 2115-26. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29382707     DOI: 10.1158/0008-5472.CAN-17-3202

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Single-Cell Intravital Microscopy of Trastuzumab Quantifies Heterogeneous in vivo Kinetics.

Authors:  Ran Li; Adel Attari; Mark Prytyskach; Michelle A Garlin; Ralph Weissleder; Miles A Miller
Journal:  Cytometry A       Date:  2019-08-19       Impact factor: 4.355

2.  Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas.

Authors:  John A Thompson; Robert J Motzer; Ana M Molina; Toni K Choueiri; Elisabeth I Heath; Bruce G Redman; Randeep S Sangha; D Scott Ernst; Roberto Pili; Stella K Kim; Leonard Reyno; Aya Wiseman; Fabio Trave; Banmeet Anand; Karen Morrison; Fernando Doñate; Christian K Kollmannsberger
Journal:  Clin Cancer Res       Date:  2018-05-30       Impact factor: 12.531

3.  Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial.

Authors:  Rakesh Popat; Dana Warcel; Jenny O'Nions; Anna Cowley; Sasha Smith; William R Tucker; Kwee Yong; Simona Degli Esposti
Journal:  Haematologica       Date:  2020-02-27       Impact factor: 9.941

Review 4.  Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies.

Authors:  Rachel Goodman; Douglas B Johnson
Journal:  Curr Treat Options Oncol       Date:  2022-09-20

Review 5.  From Pinocytosis to Methuosis-Fluid Consumption as a Risk Factor for Cell Death.

Authors:  Markus Ritter; Nikolaus Bresgen; Hubert H Kerschbaum
Journal:  Front Cell Dev Biol       Date:  2021-06-23

Review 6.  Considerations for the Nonclinical Safety Evaluation of Antibody-Drug Conjugates.

Authors:  J Edward Fisher
Journal:  Antibodies (Basel)       Date:  2021-04-19

Review 7.  Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma.

Authors:  Alessandra Romano; Paola Storti; Valentina Marchica; Grazia Scandura; Laura Notarfranchi; Luisa Craviotto; Francesco Di Raimondo; Nicola Giuliani
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

Review 8.  Unlocking the potential of antibody-drug conjugates for cancer therapy.

Authors:  Joshua Z Drago; Shanu Modi; Sarat Chandarlapaty
Journal:  Nat Rev Clin Oncol       Date:  2021-02-08       Impact factor: 65.011

9.  Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography.

Authors:  Wataru Matsumiya; Irmak Karaca; Hashem Ghoraba; Amir Akhavanrezayat; Azadeh Mobasserian; Muhammad Hassan; Jonathan Regenold; Cigdem Yasar; Michaela Liedtke; Koji Kitazawa; Quan Dong Nguyen
Journal:  Am J Ophthalmol Case Rep       Date:  2021-06-09

10.  Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody-Drug Conjugates to Increase In Vivo Efficacy.

Authors:  Jose F Ponte; Leanne Lanieri; Eshita Khera; Rassol Laleau; Olga Ab; Christopher Espelin; Neeraj Kohli; Bahar Matin; Yulius Setiady; Michael L Miller; Thomas A Keating; Ravi Chari; Jan Pinkas; Richard Gregory; Greg M Thurber
Journal:  Mol Cancer Ther       Date:  2020-11-11       Impact factor: 6.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.